Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.64 |
| ▸ | NADK | O95544 | 2/20 | 0.54 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.53 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673055 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL20419331 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL29283551 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL14253676 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL30366664 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL24420987 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL440599 | 1.00 | ADORA2A (0.64) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| Phosphoric Acid SCHEMBL16208889 | 0.95 | ADORA3 (0.59) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL7047708 | 0.89 | ADORA3 (0.54) | ADORA2AADORA3NADKHSPA5HSPA8 | |
| SCHEMBL658005 | 0.88 | ADORA3 (0.67) | ADORA2AADORA3HSPA5HSPA8HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| CN-1466591-A | Nucleoside derivatives | - | 2004-01-07 | — | — | CN | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| WO-2026106815-A1 | Z-INDUCING CHIMERA COMPOSITION | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-5811534-A | PURINE-BASED COMPOUNDS FOR INCLUSION INTO OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1998035012-A2 | METHODS AND PRODUCTS FOR ANALYZING POLYMERS | CHAN EUGENE Y (US) | 1998-08-13 | — | — | WO | disclosed |
| US-5763177-A | SELEX IS AN ACRONYM FOR SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT; USEFUL FOR DIAGNOSIS AND/OR TREATMENT OF DISEASES OR PATHOLOGICAL OR TOXIC STATES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998018430-A2 | P2Y RECEPTOR ANTAGONISTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-05-07 | — | — | WO | disclosed |
| US-5681941-A | GENETIC ENGINEERING; CROSSLINKING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| EP-0753525-A1 | CYCLIC NUCLEOTIDE DERIVATIVE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0736105-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995008003-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: PHOTOSELECTION OF NUCLEIC ACID LIGANDS AND SOLUTION SELEX | UNIVERSITY RESEARCH CORPORATION (US) | 1995-03-23 | — | — | WO | disclosed |
| US-5013829-A | Stable congener of 2',3'-dideoxyadenosine | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1991-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | ADORA2A 1754/4885ADORA3 1197/4885NADK 1715/4885 |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA2A 70/4885ADORA3 102/4885NADK 134/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA2A 70/4885ADORA3 102/4885NADK 134/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | ADORA2A 2575/4885ADORA3 1734/4885NADK 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.